LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

Strona główna・Stock List・Kymera Therapeutics Inc

Kymera Therapeutics Inc

Closed

SectorHealthcare

66.35 -0.12

Buy Sell

Overview

Share price change

24h

Current

Min

65.9

Max

66.65

Key metrics
By Trading Economics
Income	-5.6M -82M
Sales	-8.7M 2.8M
EPS	-0.94
Profit margin	-2,973.046
Employees	225
EBITDA	5.2M -79M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+14.61% upside

Market Stats
By TradingEconomics
Market Cap	541M 4.8B
Previous open	66.47
Previous close	66.35

News Sentiment

By Acuity

50%

166 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

28.34 / 33.56 Support & Resistance

Kymera Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

5 gru 2025, 21:08 UTC

Acquisitions, Mergers, Takeovers

Meta Platforms Buys AI-Device Maker Limitless

5 gru 2025, 19:39 UTC

Major Market Movers

Parsons' FAA Bid Loss Clouds Outlook After Rocky Year for Contractors

5 gru 2025, 19:17 UTC

Acquisitions, Mergers, Takeovers

Constellation Energy Agrees to Divest Assets to Finalize Calpine Deal

6 gru 2025, 16:52 UTC

Acquisitions, Mergers, Takeovers

As Netflix Swoops In to Buy Warner Bros., We Revisit the Studio's Long, Twisted Journey -- Barrons.com

6 gru 2025, 10:30 UTC

Acquisitions, Mergers, Takeovers

Why Netflix Shareholders Aren't Thrilled to Acquire Warner Bros. -- Heard on the Street -- WSJ

6 gru 2025, 02:38 UTC

Acquisitions, Mergers, Takeovers

How a Netflix-Warner Deal Would Change Everything in Hollywood -- Again -- WSJ

5 gru 2025, 21:59 UTC

Acquisitions, Mergers, Takeovers

Netflix's Megadeal Will Need the Trump Administration's Blessing -- Update

5 gru 2025, 21:50 UTC

Market Talk

Earnings

Financial Services Roundup: Market Talk

5 gru 2025, 21:50 UTC

Acquisitions, Mergers, Takeovers

The Netflix and Warner Bros. Deal Is Far From a Sure Thing -- Barrons.com

5 gru 2025, 21:36 UTC

Market Talk

Return of Shipping to Red Sea a Step Closer, Xeneta Says -- Market Talk

5 gru 2025, 21:35 UTC

Acquisitions, Mergers, Takeovers

The Netflix-Warner Bros. Deal Has a Wildcard. How Paramount Could Still Win. -- Barrons.com

5 gru 2025, 21:26 UTC

Acquisitions, Mergers, Takeovers

Warner Bros. Discovery and Netflix Enter Exclusive Deal Negotiations -- 7th Update

5 gru 2025, 21:12 UTC

Market Talk

Natural Gas Surge 9% This Week on Strong Flow of Exports -- Market Talk

5 gru 2025, 21:03 UTC

Market Talk

Earnings

Bank of Montreal Logs Solid Quarter, Though Some Unease Remains -- Market Talk

5 gru 2025, 21:01 UTC

Market Talk

Oil Caps Positive Week on Geopolitical Turmoil -- Market Talk

5 gru 2025, 20:43 UTC

Acquisitions, Mergers, Takeovers

Limitless CEO Siroker: Will No Longer Sell Pendant to New Customers

5 gru 2025, 20:43 UTC

Acquisitions, Mergers, Takeovers

Limitless CEO Siroker: Existing Pendant Customers to Be Supported for at Least Another Year

5 gru 2025, 20:42 UTC

Acquisitions, Mergers, Takeovers

Limitless CEO Dan Siroker: Limitless Has Been Acquired by Meta >META

5 gru 2025, 20:01 UTC

Acquisitions, Mergers, Takeovers

Netflix Landed a Big Deal. Now it Could Have a Big Fight. -- WSJ

5 gru 2025, 19:44 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

5 gru 2025, 19:44 UTC

Market Talk

Canada Dollar Gains Nearly 1% on Jobs Data, Rate Outlook -- Market Talk

5 gru 2025, 19:39 UTC

Market Talk

Silver Climbs to a New Record High -- Market Talk

5 gru 2025, 19:31 UTC

Acquisitions, Mergers, Takeovers

Netflix Stock Falls. Wall Street Is Worried About Warner Deal's High Price and Debt. -- Barrons.com

5 gru 2025, 18:30 UTC

Market Talk

Canada Jobless Rate Can Fall More Before Labor Slack Disappears -- Market Talk

5 gru 2025, 18:28 UTC

Acquisitions, Mergers, Takeovers

Netflix Stock Falls. Wall Street Is Worried About Warner Deal's High Price and Debt. -- Barrons.com

5 gru 2025, 18:24 UTC

Acquisitions, Mergers, Takeovers

AMC and IMAX Stocks Drop. Roku Rises. How the Netflix-Warner Bros. Deal Could Shake Up Entertainment. -- Barrons.com

5 gru 2025, 18:20 UTC

Market Talk

Baker Hughes Reports Higher U.S. Rig Count -- Market Talk

5 gru 2025, 18:11 UTC

Market Talk

The Tale of Two Canadian Employment Indicators -- Market Talk

5 gru 2025, 17:48 UTC

Market Talk

Canadian Youth Unemployment Rate Cools -- Market Talk

5 gru 2025, 17:44 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Global Equities Roundup: Market Talk

Peer Comparison

Price change

Kymera Therapeutics Inc Forecast

Price Target

By TipRanks

14.61% upside

12 Months Forecast

Average 76.35 USD 14.61%

High 98 USD

Low 53 USD

Based on 21 Wall Street analysts offering 12 month price targets forKymera Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

21 ratings

Buy

Hold

Sell

Based on 21 analysts giving stock ratings to Kymera Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

28.34 / 33.56Support & Resistance

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

Sentiment

By Acuity

166 / 374 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Kymera Therapeutics Inc

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.